A Broad Portfolio of Promising Development Candidates

Helperby has six development programmes utilising its novel ARBs, ranging from market ready to preclinical development.

Principal markets are urinary tract infections, intravenous-abdominal infections, cystic fibrosis and lung infections, prevention of post-surgical staphylococcal infections, skin infections and mouthwash.

By partnering with our Indian partners, Cadila Pharmaceuticals (HY-005 and HY-007), we aim to make our medicines affordable to patients in the East as well as the West.